CXCL12 and Stroke: Furthermore, we found that the addition of plasma SDF-1 to the basic model containing conventional risk factors also significantly improved risk reclassification for recurrent stroke (NRI: 51.77%, P = 0.006; IDI: 1.74%, P = 0.005), cardiovascular events (NRI: 42.29%, P = 0.008; IDI: 1.39%, P = 0.01), and all-cause mortality (NRI: 33.03%, P = 0.04; IDI: 0.69%, P = 0.36) at one year after stroke (Table 3).